FDA approves new orphan drug for rare cholesterol disorder

["U.S. Food & Drug Administration (FDA)" <fda@xxxxxxxxxxxxxxxxxxxxxxx>]

Title: FDA approves new orphan drug for rare cholesterol disorder

You are subscribed to FDA Press Releases for U.S. Food & Drug Administration (FDA).

This information has recently been updated and is now available.

 

FDA approves new orphan drug for rare cholesterol disorder

12/26/2012 09:32 AM EST

On Dec. 21, the U.S. Food and Drug Administration approved Juxtapid (lomitapide) to reduce low-density lipoprotein (LDL) cholesterol, total cholesterol, apolipoprotein B, and non-high-density lipoprotein (non-HDL) cholesterol in patients with homozygous familial hypercholesterolemia (HoFH). Juxtapid is intended for use in combination with a low fat diet and other lipid-lowering treatments.

.

---

Manage your FDA Subscriptions:

• Update your preferences or unsubscribe
• Questions about this service? support@xxxxxxxxxxxxxxx
• Other inquiries? webmail@xxxxxxxxxx

---

This email was sent to list-fda@xxxxxxxxxxx using GovDelivery, on behalf of: U.S. Food & Drug Administration (FDA) · 10903 New Hampshire Ave · Silver Spring, MD 20993 · 800-439-1420